Dec. 22 at 2:37 PM
$PHAR : The "Perfect Storm" Nobody is Talking About
The Breakout is Here: The Dutch ticker (
$PHARM.AS) just shattered resistance at €1.44 (+2.8%). The US ADR is lagging, creating a massive arbitrage opportunity before the open.
Why this isn't just a trade, but a Multi-Bagger:
The "Cash Cow" Defense: While other bios burn cash, PHAR just posted
$15.8M Operating Profit (+285% YoY) and generated
$32M in free cash flow in Q3 alone.
The Monopoly:
$JOENJA is the ONLY approved drug for APDS. Q3 sales jumped 35%. Pediatric approval (PDUFA) is locked for Jan 31.
The Supply Shock: With <0.1% Institutional Ownership on the US ticker, there are NO sell walls. No big funds to dump shares. Once retail volume hits, the float evaporates.
Bottom Line: Profitable. Growing 30%. Trading at ~3x Sales. We are buying a money-printing machine at a penny-stock valuation. The gap closes today
